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Medication use and the risk of motor 
vehicle collision in West Virginia drivers 65 years 
of age and older: a case-crossover study
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Abstract 
Background: The current generation of older adults reports a higher lifetime prevalence of prescription, over-the-
counter, and recreational drug use. The purpose of this analysis is to characterize the drug usage and determine the 
risk of motor vehicle collision associated with individual medications in a population of drivers ≥65 years.
Methods: A case-crossover study was conducted at West Virginia University Healthcare’s facilities using data 
obtained from the electronic health records (n = 611) of drivers ≥65 years admitted for medical treatment following 
a motor vehicle collision which occurred between Jan. 1, 2009 and June 30, 2014. Patients’ medication usage 14 days 
before collision were matched and compared to their medication usage during four control periods prior to collision. 
Odds ratios were then calculated for the most prevalent individual medications and pharmaceutical sub-classes using 
conditional logistic regression.
Results: Analgesic, cardiovascular and gastrointestinal medicines were common. Few drivers tested positive for 
either licit or illicit drugs. Of those testing positive for drugs, benzodiazepines and opiates were prevalent. Drivers 
consuming Tramadol (adjusted OR 11.41; 95 % CI 1.27, 102.15) were at a significantly increased risk of motor vehicle 
collision.
Conclusions: Older adult drivers who have a prescription for this medication may need to be aware of the potential 
risk. Further research is necessary in a larger, more nationally representative population.
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Background
The United States (US) is experiencing an unprecedented 
demographic shift as the number of adults 65  years of 
age and older (i.e. seniors) are the most rapidly growing 
subgroup of the population [1]. By 2020, it is estimated 
that the number of licensed drivers over 65 years of age 
will exceed 40 million [2]. This demographic shift poses 
a unique challenge to both public health and traffic safety 
officials as senior drivers experience more motor vehicle 
fatalities [3] and an increased rate of injurious crashes 
per mile driven [4].
It is also well-established in the literature that medi-
cation usage increases with age. In the US, adults over 
65  years of age consume more than 30  % of all annual 
written prescriptions [5]. The current generation of 
older adults reports a higher prevalence of both lifetime 
legal and illegal drug use compared to previous genera-
tions [6]. As more adults continue to drive later in life 
compared to previous generations, concerns regard-
ing how these drugs affect driving ability are beginning 
to amass [7, 8]. While alcohol is a known contributor of 
motor vehicle collisions, the extent to which drugs other 
than alcohol contribute to crashes is less lucid [9]. There 
is evidence that driving under the influence of drugs is 
increasing nationally and that commonly prescribed pre-
scription medications, some of which may interfere with 
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safe driving, are becoming more ubiquitous than tradi-
tional illegal drugs among fatality injured drivers [10, 11].
The association between medications and motor vehi-
cle collisions is largely understudied in the US [7, 8], par-
ticularly among senior drivers [12]. This issue may be of 
particular relevance to residents of West Virginia. The pop-
ulation of West Virginia is more mature compared to other 
states where ~16 % of the state’s residents are over 65 years 
of age [13] compared to ~13 % in the US population [14]. 
Previous research has also shown that both legal and ille-
gal drug use contribute greatly to motor vehicle collisions 
in West Virginia [9]. The traffic fatality rate is also starkly 
higher—nearly 45 % more—compared to other non-Appa-
lachian states [15]. Therefore, the purpose of this analysis is 
to explore which prescription and over-the-counter medi-
cations are most common, if illegal drug use is prevalent, 
and which prescription and over-the-counter medications 
are associated with an increased risk of motor vehicle col-
lision among West Virginia drivers 65 years of age or older. 
While the intent of drug use is often impossible to deter-
mine, prescription and over-the-counter-medications will 
be referred to as ‘licit drugs’ in this analysis because it shall 
be assumed that these substances were taken to remedy a 
medical condition and obtained from a legal facility; ‘illicit 
drugs’ will refer to traditional illegal drugs, such as meth-
amphetamine, cocaine, etc., which are often obtained ille-
gally, abused, and have no real medical benefit. Discerning 
this information may help guide future interventional and 
educational efforts to minimize death and disability from 
motor vehicle collisions in this population.
Methods
Study design
The design used for this analysis was a case-crossover. 
Developed by Maclure in 1991, case-crossover studies 
are similar to matched case–control studies in theory; the 
fundamental difference between the two study designs is 
that cases serve as their own controls in a case-crosso-
ver study [16]. The case-crossover design compares (i.e. 
matches) a case’s exposure during a time period imme-
diately preceding an event (i.e. the case or ‘risk’ period) 
to the exposure in a time period when the event did not 
occur (i.e. control period) [16]. These designs are useful 
for studying the relationship between transient exposures 
and acute outcomes; they are commonly used in air pol-
lution studies, traffic safety, and pharmacoepidemiology 
[17]. A benefit of the case-crossover design is that fixed 
confounders, such as age, race, sex, etc., are controlled 
for regardless if they were actually measured [18].
The sampling schema used for this analysis is depicted 
in Fig. 1. The event of interest was a motor vehicle colli-
sion in which the driver required medical treatment. The 
exposure of interest was the driver’s medication usage 
leading up to the collision. The risk period was defined 
as the 14 days preceding the motor vehicle collision. The 
reason as to why 14 days was chosen as the risk period as 
opposed to a shorter duration was because medications 
may take time to accumulate and/or cause side-effects in 
an individual which may interfere with their driving abil-
ity. Additionally, this length of risk period has been used 
in previous studies [19]. In order to increase statistical 
efficiency [20], there were four matched control periods, 
each 15  days long, at 350–365, 255–270, 165–180, and 
75–90  days before the collision. Control periods were 
chosen to be disjoint from one another to avoid possible 
correlation [21].
Study setting
All cases received medical treatment from West Vir-
ginia University (WVU) Healthcare’s facilities located in 
Fig. 1 Overview of sampling schema for case and control periods
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Morgantown, WV. Morgantown is a city with approxi-
mately 29,600 residents situated in Monongalia county 
in north-central West Virginia [22]. The size of the town 
can fluctuate throughout the year as it is home of West 
Virginia University, the state’s largest institution of higher 
education. In 2012, approximately 25.1 % of the patients 
served by WVU Healthcare resided in Monongalia 
county, while an additional 21.5 % of patients lived in sur-
rounding counties (i.e. Preston, Marion, and Taylor coun-
ties) [23]. Approximately 38  % of patients who sought 
treatment from WVU Healthcare were from other West 
Virginia counties, while another ~15 % of patients were 
from surrounding states (i.e. Pennsylvania, Maryland, 
Ohio, Virginia and Kentucky) [23]. Therefore, the popu-
lation served by WVU Healthcare is fairly representative 
of the state. The population of West Virginia is predomi-
nately of white non-Hispanic race/ethnicity and is com-
prised largely of older individuals [22]. In 2010, heart 
disease, cancer, and chronic lower respiratory disease 
were the leading causes of death in this population [22].
Data sources and collection
All data for this analysis were collected from the elec-
tronic medical records of eligible cases and obtained 
through Medsite and Epic (Merlin), WVU Healthcare’s 
electronic medical record systems. Data was collected 
through a combination of manual data abstraction and 
through the assistance of the West Virginia University 
Clinical and Translational Science Institute’s (WVCTSI) 
Integrated Data Repository. In order to ensure the con-
gruence of the data obtained from WVCTSI and the 
actual medical records, several electronic records were 
pulled and compared to ensure accuracy. This study 
was approved by West Virginia University’s Institutional 
Review Board (protocol #1401165743).
Case selection
The sampling frame consisted of individuals 65 years of 
age and older at time of treatment and received treat-
ment from emergency or trauma services or urgent care 
facilities from January 1, 2009 to June 30, 2014. Cases had 
to be designated as a driver involved in a motor vehicle 
collision by the International Classification of Disease, 
Ninth Revision, Clinical Modification codes (ICD 9-CM) 
E810.0, E811.0, E812.0, E813.0, E814.0, E815.0, E816.0 
and E819.0. The E-codes used to identify the incident 
cases could have been listed as the primary or secondary 
diagnosis in the electronic medical record.
Medication exposures
Medications of interest were those considered potentially 
driver-impairing, meaning that they could possibly alter 
a driver’s cognition, psychomotor function, or physical 
functioning as suggested by the American Medical Asso-
ciation [24]. Medication usage up to a year before each 
case’s admittance for treatment was assessed. Medica-
tions that were started up to 24 h before admittance for 
treatment were not included in the analysis; this was 
done to avoid potential bias in the event that a medica-
tion was administered to a patient by emergency medical 
services (i.e. the medication was consumed after the col-
lision occurred). The duration of time that an individual 
was taking a particular medication was obtained directly 
from the medical record. If the duration of medication 
usage could not be determined or was not documented in 
the record, the medication was not included in the analy-
sis as to avoid misclassification. As many of the cases 
were existing patients of WVU Healthcare and/or due to 
the severity of the incurred injuries, medication records 
were fair in terms of completeness. Of the 611 case visits 
included in this analysis, 581 (95  %) cases had medica-
tions noted in their electronic health record at any point, 
while 292 (48 %) cases had medication usage in the year 
preceding their motor vehicle collision. Of these indi-
viduals, 286 (47 %) were taking a medication during the 
risk/case period. An individual was considered ‘exposed’ 
if they were taking a medication at any point during the 
case and/or individual control periods.
While the purpose of this analysis was to explore the 
risk of motor vehicle collision due to individual medi-
cation exposures, an analysis of more encompassing 
pharmaceutical sub-classes was also conducted. This 
included anticholesteremics, anticoagulants, antidepres-
sants (non-benzodiazepines), antihyperglycemics, anti-
hypertensives, narcotic analgesics, and benzodiazepines. 
In this particular analysis, anticholesteremics included 
3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors. 
Anticoagulants included both coumarin type and platelet 
aggregation inhibitors. Antidepressants included tricyclic 
antidepressants, selective serotonin re-uptake inhibitors, 
serotonin antagonist and reuptake inhibitors, serotonin–
norepinephrine reuptake inhibitors, norepinephrine-
dopamine reuptake inhibitors, and noradrenergic and 
specific serotonergic antidepressants. Antihypergly-
cemics included insulin, biguanides, insulin-release 
stimulants, combination biguanides and insulin-release 
stimulants, and thiazolidinediones. Antihypertensives 
included angiotensin-converting-enzyme inhibitors, 
angiotensin receptor antagonists, and sympatholytic vas-
odilators. Narcotic analgesics also included narcotic-non 
salicylate combinations, and anesthetic adjunct agents.
Other covariates
Other variables of interest, which could help describe 
the population, included age, gender, race, day, time, 
year, and season of admittance, how the patient was 
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transported to medical treatment, treatment location, 
injury severity, insurance status of the patient, county 
and state of residence, employment status, length of 
hospital stay, and health status. The categorization of 
these variables is presented in Table  1. For season of 
admittance, winter included December, January, and 
February, while spring comprised March, April, and 
May. Summer included June, July, and August while fall 
included September, October, and November. Treat-
ment location was grouped into trauma, emergency or 
urgent care departments; because so few patients were 
seen by urgent care (i.e. less than 10), urgent care and 
emergency were reported together to protect patient 
confidentiality. Patient’s injury severity was based on 
acuity level at time of arrival for treatment. Patient 
acuity levels that were noted as emergent or immedi-
ate were classified as severe injuries. Acuity levels that 
were urgent were classified as moderate injuries. Acui-
ties that were less urgent or non-urgent were classified 
as minor injury severity. Since acuity is not assigned 
within the Urgent Care facility, these were left unas-
signed. Insurance status of the patient was grouped as 
government, private, none, or other/unknown. Govern-
ment insurance included Medicare or Medicaid pro-
grams. Private insurance indicated that a patient had 
a commercial insurance plan. Employment/work sta-
tus was categorized as retired or employed. If a patient 
reported that they were still working full, part-time or 
were self-employed, employment status was catego-
rized as employed. Chronic disease status was catego-
rized as 0, 1–3, or 4 or more based on the number of 
chronic conditions patients were noted to have in their 
medical records. For patient confidentiality purposes, 
these conditions were grouped as opposed to list-
ing each individually. The chronic conditions of inter-
est, along with Clinical Classification Software codes 
or ICD 9-CM codes used to identify them in patients’ 
records, were as follows: heart disease (96, 97, 100, 101, 
103–108, 114, 117), stroke (109, 111, 112, 113), demen-
tia (653), Alzheimer’s disease (331.0), diabetes (49,50), 
cancer (11–44), arthritis (201–203), Parkinson’s dis-
ease (79), hypertension (98–99), asthma (128), chronic 
obstructive pulmonary disease (127), alcoholism (660), 
depression (296.2, 296.3, 311), anxiety (651), chronic 
kidney disease (158), and substance abuse/dependency 
(661). As part of the admission process, patient’s urine 
may have been laboratory tested for the presence of 
alcohol and/or drugs. The drugs that could be detected 
were amphetamines, barbiturates, benzodiazepines, 
buprenorphine, cannabis, cocaine, opiates, phencycli-
dine and propoxyphene. Results of drug testing were 
also noted (Table 3).
Table 1 Demographic characteristics of patients




 65–69 225 (36.8)
 70–79 252 (41.2)
 80–89 119 (19.5)
 ≥90 15 (2.5)
Gender
 Male 330 (54.0)
 Female 281 (46.0)
Race
 White 560 (97.0)
 Other 17 (3.0)
 Missing 34
Day of admittance
 Mon–thurs 368 (60.2)
 Fri–sun 243 (39.8)
Time of admittance
 7:00 AM–6:59 PM 462 (75.7)
 7:00 PM–6:59 AM 148 (24.3)
Season of admittance
 Winter 133 (21.8)
 Spring 189 (30.9)
 Summer 147 (24.1)
 Fall 142 (23.2)
Year of admittance
 2009 102 (16.7)
 2010 87 (14.2)
 2011 89 (14.6)
 2012 154 (25.2)
 2013 110 (18.0)
 2014 69 (11.3)
Method of transport
 Ambulance 248 (40.6)
 Helicopter 62 (10.2)
 Self 37 (6.1)
 Other/unknown 264 (43.2)
Treatment location
 Trauma 135 (22.1)
 Emergency and urgent care 476 (77.9)
Injury severity
 Minor 29 (9.0)
 Moderate 43 (13.4)
 Severe 250 (77.6)
 Unknown 289
Insurance status
 Government 331 (54.2)
 Private 181 (29.6)
 None 30 (4.9)
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Statistical methods
Because of the 1:4 matching of case to control periods, 
conditional logistic regression was used to calculate the 
odds of motor vehicle collision for each medication expo-
sure [25]. Because of the study design (i.e. known longi-
tudinal medication exposure over time), the odds ratio 
approximated the incidence rate ratio (i.e. risk) [26]. To 
account for the slight difference in exposure lengths of 
case and control periods (i.e. 14 versus 15 days, respec-
tively), the natural log of exposure time in days was 
used as the variable offset as suggested by Greenland 
[25]. Because case-crossover studies are not immune to 
within person confounding, all regression models were 
adjusted for the number of medications (both prescrip-
tion and over-the-counter) a case was taking during each 
risk and control period. The number of medications used 
served as a proxy of health status as a case’s health may 
have been time-varying (i.e. improved or declined) over 
the study period. Analyses could not be adjusted for the 
number of chronic conditions a case possessed as this did 
not change over the study period. All analyses were run 
using SAS/STAT Software version 9.3 [27], with α = 0.05.
Results
The demographic characteristics of cases and the cir-
cumstances surrounding their medical visits (n =  611) 
are presented in Table  1. The majority of cases were 
aged 65–69 (36.8  %) or 70–79  years (41.2  %) at time of 
treatment. More males (54.0  %) than females (46.0  %) 
were admitted for treatment post-collision and most were 
of white race (97.0 %). As less than 10 patients were seen 
at urgent care, most patients were treated in the emer-
gency department as opposed to trauma service (22.1 %), 
though many of the injuries sustained were moderate to 
severe. Most patients had government (54.2  %) or pri-
vate (29.6 %) insurance coverage. The majority of patients 
were West Virginia residents (80.4  %). While most 
patients were no longer working, 12.4  % still held some 
form of employment. Chronic conditions (i.e. 1 or more) 
were common (82.4 %).
Analgesic, cardiovascular and gastrointestinal medi-
cations were the most prominent therapeutic groups 
observed during case and control periods (Table  2). As 
for specific medications, Aspirin, Metoprolol, Lisinopril, 
and Furosemide were the most common. A combination 
of Oxycodone and Acetaminophen was the most com-
mon dual-drug compound.
Only 32  % of patients were tested for drugs at time 
of admittance, while slightly more were tested for alco-
hol (Table 3). Overall, traditionally illicit drugs were not 
detected in cases. Among those testing positive, benzodi-
azepines and opiates were the most detected substances. 
Approximately, 50  % of individuals testing positive for 
opiates or benzodiazepines had a traceable prescription 
for these substances in the past year before collision.
After adjusting for the number of medications (pre-
scription and non-prescription) a driver was taking dur-
ing each case and control period (Table  4), individuals 
(N = 11) who were taking Tramadol (OR = 11.41; 95 % 
SD standard deviation
Table 1 continued
Characteristic Patient visits 
(N = 611)
N (%)
 Other/unknown 69 (11.3)
County of residence
 Monongalia 92 (15.4)
 Other 506 (84.6)
 Missing 13
State of residence
 WV 491 (80.4)
 Other/missing 120 (19.6)
Work status
 Employed 74 (12.4)
 Retired 523 (87.6)
 Missing 14
Number of chronic conditions
 0 108 (17.6)
 1–3 314 (51.4)
 ≥4 189 (31.0)
 Average length of stay (days ± SD) 1.9 ± 4.9
Table 2 Most frequently identified medications dur-
ing case and control periods
Total cases (N = 611) Number and per-
centage of cases 
taking these drugs 
N (%)
Broad therapeutic groups
 Analgesics 82 (13.4)
 Cardiovascular 81 (13.3)
 Gastrointestinal 74 (12.1)
 Psychotherapeutics 48 (7.9)
Specific medications
 Metoprolol 38 (6.2)
 Aspirin 33 (5.4)
 Esomeprazole 30 (4.9)
 Lisinopril 27 (4.4)
 Furosemide 21 (3.4)
Combinations
 Oxycodone and Acetaminophen 20 (3.3)
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CI 1.27, 102.15) were at a significantly increased risk of 
motor vehicle collision while taking this substance dur-
ing the risk period compared to control periods. Though 
not statistically significant, those taking Clopidogrel, 
Gabapentin, Citalopram, Insulin, Hydrochlorothiazide, 
Metoprolol, Zolpidem, and Nitroglycerine were trending 
towards an increased risk of collision.
Table  5 lists larger therapeutic classes of medications 
along with subsequent crude and adjusted odds ratios 
and 95  % CI to approximate the risk of an individual’s 
involvement in a motor vehicle collision while taking 
these substances during the risk period compared to con-
trol periods. After adjusting for the number of medica-
tions a driver was taking during each case and control 
period, all therapeutic classes were not found statistically 
significant. Although those taking anticoagulants, antihy-
perglycemics, and antihypertensive medications during 
case periods were trending towards an increased risk of 
motor vehicle collision compared to control periods.
Discussion
Two principal findings were generated as a result of this 
analysis. First, while few patients were tested for drugs 
at time of medical treatment, the drivers found drug-
positive tended to test positive for common prescription 
medications. Typical illegal drugs, such as cocaine or 
phencyclidine, were not commonplace in this population. 
Second, despite small sample sizes, those taking Trama-
dol (N  =  11) were at a significantly increased risk of 
motor vehicle collision if they took this substance 14 days 
prior to collision compared to control times. Numer-
ous other medications were also trending towards an 
increased risk of motor vehicle collision, but were likely 
not found statistically significant due to small sample 
sizes and low statistical power. While it is possible that 
the medical conditions for which these drugs were pre-
scribed may have influenced a patient’s driving ability, 
these findings may be of important clinical relevance and 
worthy of further exploration in a larger population.
Trend analyses have shown that prescription medica-
tions, particularly benzodiazepines and narcotic analge-
sics, are being detected more frequently than traditional 
illicit substances, such as cocaine and methamphetamine, 
among drug-positive drivers in the US [10, 11]. While the 
literature regarding drug usage among older adult driv-
ers is limited, previous research has suggested that illicit 
drug usage may not be common among this population. 
A study of drug usage among level one trauma patients 
over 60 years of age involved in motor vehicle collisions 
(n =  180) in Tennessee during the 1990’s revealed that 
alcohol and illicit drugs were detected in only 14 and 
1  %, respectively, of study participants [28]. Therefore, 
the findings from this analysis were similar. The current 
analysis also showed that approximately 50 % of patients 
had a traceable prescription for benzodiazepine or opi-
ates within the year before collision. It is possible that the 
other 50  % of drivers received a prescription outside of 
WVU Healthcare network, consumed pills left over from 
older prescriptions, possibly from sharing medications, 
obtained them illegally, or simply had incomplete docu-
mentation in their medical records. This finding may be 
worthy of additional exploration.
As for the risk of motor vehicle collision posed by indi-
vidual medications, two previous studies have investi-
gated the risk of motor vehicle collision associated with 
the use of Tramadol [29, 30]. In the study by Bachs et al., 
Tramadol use was not significantly associated with an 
increased risk of motor vehicle collision among a Norwe-
gian cohort of adult drivers aged 18–70 years, though it 
was trending in the direction of increased risk (Risk 1.5; 
95 % CI 0.9, 2.3). In the study by Gibson et al., Tramadol 
was significantly associated with an increased risk of col-
lision (Risk 9.17; 95 % CI 7.81, 10.77) in an English cohort 
of drivers aged 18–74 years. At high doses, Tramadol is 
also known to affect balance [31]. Poor balance has also 
been linked to an increased risk of motor vehicle colli-
sion, particularly in older populations [32]. Therefore, the 
effects of Tramadol are likely not age-dependent because 
this analysis was limited to older adult drivers whereas 
other studies investigated drivers less than 74 years of age 
and the results were comparable.
Numerous other medications in this study were also 
trending towards an increased risk of motor vehicle colli-
sion, but were not found statistically significant included: 
Clopidogrel, Gabapentin, Citalopram, Insulin, Hydro-
chlorothiazide, Metoprolol, Zolpidem, and Nitroglycerin. 
To the authors’ knowledge, no studies have investigated 
whether Clopidogrel, an anticoagulant, affects driving 
ability. Two studies have investigated the relationship 
between anticoagulants as a pharmaceutical sub-class 
Table 3 Alcohol and/or drugs identified in  cases via  labo-
ratory testing at time of admittance
Patients could be tested for the following drugs: amphetamines, barbiturates, 
benzodiazepines, buprenorphine, cannabis, cocaine, opiates, phencyclidine 
and propoxyphene. Benzodiazepines and opiates were the only drugs detected 
among patients tested










Alcohol 269 (44.0) 12 (4.5) –
Drugs 194 (31.8) 61 (31.4) –
Benzodiazepines 194 (31.8) 33 (17.0) 16 (48.5)
Opiates 194 (31.8) 30 (15.5) 15 (50.0)
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and the risk/odds of motor vehicle collision. A case–
control study conducted by McGwin et  al. showed that 
elderly drivers in Alabama during 1996 who consumed 
anticoagulants were 2.6 times more likely to be involved 
in a motor vehicle collision (OR 2.6; 95  % CI 1.0, 6.7) 
[1]. As to which medications were included in this cat-
egorization was not described. A case–control study 
conducted by Delaney et al. in Quebec, Canada showed 
that those taking Warfarin, another anticoagulant, were 
not at an increased risk of motor vehicle collision (OR 
0.74; 95 % CI 0.55, 1.05) [33], which was similar to what 
was seen in this analysis. Gabapentin, a newer anti-epi-
leptic medication, is not known to affect driving ability, 
though it may. In a study conducted by Martin et  al., 
healthy senior adults (mean age 66.5 years) experienced 
mild cognitive effects during psychomotor testing con-
ducted in a laboratory setting [34]. Common complaints 
regarding Gabapentin use include dizziness, nausea, 
and somnolence [35], which could affect one’s ability to 
drive. While Citalopram has not been associated with 
an increased risk of motor vehicle collision in two other 
studies [30, 36], second-generation antidepressants as 
Table 4 The risk of involvement in a motor vehicle collision by medication exposure
a Conditional logistic regression was used to calculate the odds ratios and 95 % CI. Each case’s medication exposure during the 14 day risk period immediately 
before the crash was matched to four separate control periods up to 1 year before the collision to assess if medication use during the risk period was associated with 
an increase of motor vehicle collision compared to control periods. Model 1 is the crude estimate (i.e. unadjusted) while Model 2 was adjusted for the number of 
medications a person was taking during each case and control period
Medication Number of individuals  
taking medication (N)
1:4 Matched control periodsa
Model 1 OR (95 % CI) Model 2 OR (95 % CI)
Anticholesteremic
 Simvastatin 12 1.00 (0.12, 8.17) 0.42 (0.03,07.23)
Anticoagulants
 Clopidogrel 10 10.73 (1.19, 96.67) 7.62 (0.48, 122.10)
 Warfarin 10 0.72 (0.06, 9.04) 0.30 (0.08, 1.22)
Anticonvulsants
 Gabapentin 15 2.69 (0.59, 12.32) 1.32 (0.24, 7.17)
Antidepressants
 Citalopram 10 3.01 (0.31, 29.65) 3.21 (0.24, 42.50)
Antihyperglycemics
 Insulin 12 15.76 (1.78, 139.61) 2.63 (0.14, 48.72)
Antihypertensive
 Furosemide 12 0.50 (0.08, 3.22) 0.81 (0.06, 10.62)
 Hydrochlorothiazide 13 12.35 (1.35, 113.06) 15.01 (0.76, 296.60)
 Lisinopril 25 1.56 (0.43, 5.69) 0.27 (0.05, 1.60)
 Metoprolol 29 5.29 (1.31, 21.38) 1.16 (0.23, 5.79)
Muscle relaxants
 Albuterol 11 0.44 (0.06, 3.20) 0.25 (0.02, 3.34)
Narcotic analgesics
 Hydrocodone 15 1.32 (0.36, 4.92) 0.37 (0.04, 3.79)
 Tramadol 11 10.56 (1.17, 95.51) 11.41 (1.27, 102.15)
Sleep medications
 Zolpidem 10 4.20 (0.73, 24.13) 1.42 (0.66, 3.00)
 Steroids
Fluticasone 11 0.56 (0.08, 3.89) 0.41 (0.04, 4.85)
 Prednisone 12 0.12 (0.01, 1.07) 0.19 (0.02, 1.82)
Vasodilators
 Nitroglycerin 12 2.54 (0.42, 15.23) 1.27 (0.07, 23.82)
Other drugs
 Alendronate 10 1.15 (0.22, 6.04) 0.13 (0.01, 1.78)
Combination drugs
 Oxycodone and Acetaminophen 16 0.61 (0.18, 2.00) 0.17 (0.02, 1.63)
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a pharmaceutical sub-class are known to effect driving 
ability possibly due to side effects produced after ini-
tial use [37]. It is possible that those taking Citalopram 
in this analysis were experiencing side-effects, though 
this is unknown. Several studies have investigated the 
association between Insulin use and the risk of motor 
vehicle collision [1, 38–42]. Most of the findings con-
cerning Insulin use are mixed. Two studies have found 
significantly increased risks of motor vehicle collision 
with Insulin use [38, 40], while four others have found 
no significant associations [1, 39, 41, 42]. To the authors’ 
knowledge, no studies have investigated the risk of motor 
vehicle collision associated with individual antihyperten-
sive medications. One study by McGwin et al. did inves-
tigate the use of angiotensin-converting enzyme (ACE) 
inhibitors, beta-blockers, and diuretics, which all can be 
used to treat hypertension [1]. After adjusting for age, 
sex, race, and annual miles driven, the odds of motor 
vehicle collision were 1.6 (95 % CI 1.0, 2.7), 1.4 (95 % CI 
0.8, 2.3), and 0.9 (95  % CI 0.5, 1.7) for ACE inhibitors, 
beta blockers, and diuretics, respectively [1]. In this anal-
ysis, Hydrochlorothiazide, a diuretic, and Metoprolol, a 
beta blocker, were both trending toward being associated 
with an increased risk of motor vehicle collision. While 
the pharmacokinetic properties of these drugs may be a 
potential explanation, the reason as to why the effects of 
Hydrochlorothiazide on motor vehicle collision were so 
pronounced is unknown. Zolpidem, a sleep-promoting 
medication, has consistently shown in three other studies 
to be associated with an increased risk of motor vehicle 
collision [32, 43, 44]. While no studies have investigated 
the effects of individual vasodilators, such as Nitroglyc-
erin, on motor vehicle collision, only one study investi-
gated them as a pharmaceutical sub-class. Mcgwin et al. 
found that vasodilators as a sub-class were not associ-
ated with an increased risk of collision [1]. The reason 
as to why Nitroglycerin use in this analysis was trend-
ing towards an increased risk of motor vehicle collision 
remains unknown.
The findings from this analysis have several key clini-
cal implications. While these results are not conclusive, it 
may be worthy of notifying older patients who have pre-
scriptions for these medications of their potential risk, 
particularly if they drive frequently. Future interventional 
efforts could involve raising patient awareness. Secondly, 
the findings of this study may suggest that drugs within 
the same pharmaceutical class maybe more or less driver 
impairing than others. This may be worthy of consid-
eration to clinicians when prescribing medications to 
patients who drive frequently.
The findings from this analysis do need to be inter-
preted with caution as disease-medication relationships 
are often difficult, if not impossible, to distinguish. It is 
entirely possible that the disease in which the medica-
tions were prescribed could be affecting one’s ability to 
drive. Numerous medical conditions have been asso-
ciated with motor vehicle collision, particularly sleep 
apnea [45], dementia [46], arthritis [47], diabetes [48], 
epilepsy [48], anxiety [49], depression [49], and Parkin-
son’s disease [50]. In addition, drugs that affect the cen-
tral nervous system may exhibit different effects among 
individuals. There are numerous intrinsic and extrinsic 
factors that can alter medication effectiveness and/or side 
effects among individuals. These include, but are not lim-
ited to, drug solubility [51], intestinal pH [51], drug inter-
actions [52], age [53], sex [53, 54], weight [53], diet [55, 
56], genetics [57], circadian rhythms [58], supplement 
use [59], health of the individual [60], developed toler-
ance [61], dosage [62], route of administration [62], etc.
Several of these factors which may alter a drug’s effec-
tiveness were controlled for by study design; the strength 
case-crossover studies are that all fixed confounders are 
Table 5 Risk of involvement in a motor vehicle collision by medication exposure categorized by pharmaceutical sub-class
a Conditional logistic regression was used to calculate the odds ratios and 95 % CI. Each case’s medication exposure during the 14 day risk period immediately before 
the crash was matched to four separate control periods up to one year before the collision to assess if medication use during the risk period was associated with 
an increase of motor vehicle collision compared to control periods. Model 1 is the crude estimate (i.e. unadjusted) while Model 2 was adjusted for the number of 
medications a person was taking during each case and control period
Medication sub-class Number of individuals  
taking medication (N)
1:4 Matched control periodsa
Model 1 Odds ratio (95 % CI) Model 2 Odds ratio (95 % 
CI)
Anticholesteremics 31 1.50 (0.44, 5.18) 0.42 (0.08, 2.21)
Anticoagulants 20 3.59 (0.84, 15.28) 2.29 (0.35, 15.19)
Antidepressants 30 2.05 (0.59, 7.16) 0.50 (0.09, 2.67)
Antihyperglycemics 22 15.36 (1.79, 132.0) 2.24 (0.17, 29.84)
Antihypertensives 39 3.32 (1.15, 9.62) 1.24 (0.29, 5.32)
Benzodiazepines 21 1.96 (0.58, 6.62) 0.71 (0.15, 3.34)
Narcotic Analgesics 41 1.56 (0.72, 3.39) 0.94 (0.32, 2.75)
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controlled. Despite this strength, this study has several 
distinct limitations. First, certain time-varying covariates 
were not adjusted for as many of them were immeasur-
able. For example, driving exposure (i.e. the amount that 
an individual drives), is a known and important con-
founder of traffic studies [63] and could not be accounted 
for in this analysis because it is absent from the medical 
records. Second, there were limitations associated with 
the medical records. Much of the information collected 
was self-reported by the patient or their legal guard-
ian and subject to recall bias. Some of the information, 
such as medication duration, may have been incomplete 
or was simply not documented. Also, the accuracy of 
E-codes for identifying potential cases in this analysis 
may have been lacking [64]; therefore some potential 
cases may have been unnecessarily excluded particu-
larly if the patient was not coded properly. Third, patient 
behavior was unknown; it was impossible to determine if 
the patient was taking their medication as prescribed by 
their healthcare provider. Fourth, the sample sizes in this 
analysis were often small and many statistical tests were 
likely under-powered. Also, several regression analy-
ses were run, so statistical significance could have been 
achieved by chance alone. Fifth, as this study was con-
ducted in only one state, the findings may not be general-
izable to other locations. Sixth, as previously mentioned, 
disease-medication relationships are often difficult to dis-
tinguish. The findings of this analysis are not suggesting 
that the medications were the cause of the motor vehi-
cle collision; the findings are associative. Future research 
may involve replicating this study in a larger population 
that is nationally representative.
Conclusion
This analysis sought to characterize drug usage and 
determine which individual medications were associated 
with an increased risk of motor vehicle collision among 
West Virginia drivers 65  years of age or older using a 
case-crossover approach. It was determined that analge-
sics, cardiovascular and gastrointestinal drugs were prev-
alent in this population. While few drivers were tested, 
illicit drug use was uncommon. Those taking frequently 
prescribed medications, such as Tramadol, were at a sig-
nificantly increased risk of motor vehicle collision while 
taking these substances during the 14  day risk period 
compared to control periods. Future research in this area 
is necessary as different medications may pose more risk 
to patient safety than others. The association between 
medication use and the risk of motor vehicle collisions is 
particularly important considering that drivers are living 
longer and maintaining their mobility later in life despite 
their medical conditions.
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